Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Biohaven Ltd.NYSE: BHVN

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables remains negative

Q2 FY2026 net receivables was $0, compared with $0 a year earlier.

Context

  • Net receivables amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Net receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoJun 2025
$0— since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Net Receivables vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Net receivables amounts to 0.0% of total assets for BHVN, versus a peer median of 0.7%.
BHVN Competitors
Net Receivables for BHVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMCRImmunocore Holdings plcMar 2026$81.07M USD+28.5%+9.0%7.6%
ABCLAbCellera Biologics Inc.Sep 2026$67.28M USD-57.8%+14.0%4.5%
XERSXeris Biopharma Holdings, Inc.Mar 2026$56.3M USD+21.5%+18.3%14.4%
NTLAIntellia Therapeutics, Inc.Mar 2026$9.13M USD-13.1%+36.0%1.2%
PHVSPharvaris N.V.Sep 2026€5.98M EUR+103.7%+128.3%2.0%
ZBIOZenas BioPharma, Inc.Mar 2026$1.1M USD——0.1%
CLDXCelldex Therapeutics, Inc.Sep 2026$355K USD+294.4%+79.7%0.0%
BHVNBiohaven Ltd.Jun 2026$0 USD——0.0%
IMNMImmunome, Inc.Sep 2026$0 USD——0.0%
VERAVera Therapeutics, Inc.Jun 2026$0 USD-100.0%—0.0%
SIONSionna Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding BHVN) —+21.5%+27.1%0.7%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents76.06M204.88M248.4M99.13M229.96M
Short-term Investments0260.46M133.42M386.86M89.18M
Net Receivables046.14M13.25M2.6M0
Inventory00000
Other Current Assets12.03M54.54M12.13M508K2.17M
Total Current Assets94.82M586.97M442.45M538.47M368.33M
Property, Plant & Equipment (Net)17.68M52.44M48.58M53.71M15.96M
Goodwill1.39M1.39M1.39M1.39M1.39M
Intangible Assets18.95M18.4M18.4M18.4M18.4M
Long-term Investments6M0000
Tax Assets00000
Other Non-current Assets3.22M2.59M2.4M3.13M47.36M
Total Non-current Assets47.24M74.82M70.77M76.64M83.12M
Total Assets142.06M661.78M513.21M615.11M451.45M
Account Payables4.78M10.7M15.58M18.03M11.64M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities9.54M14.6M35.7M84.71M59.49M
Total Current Liabilities41.94M90.02M55.42M154.23M115.93M
Long-term Debt0000238.9M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.64M2.41M2.25M4.66M4.58M
Total Non-current Liabilities5.44M32.99M29.81M37.45M283.44M
Total Liabilities47.37M123.01M85.24M191.67M399.38M
Common Stock34.69M615.74M887.53M1.66B1.93B
Retained Earnings0(91.12M)(499.29M)(1.35B)(2.08B)
Accumulated OCI0284K(65K)79K8.35M
Other Stockholders Equity00000
Minority Interest60M0000
Total Equity94.69M538.77M427.98M423.44M52.07M
Total Debt3.24M33.6M30.88M36.58M284.61M
Net Debt(72.82M)(171.28M)(217.53M)(62.55M)54.66M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.